Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study. ...